Hospitals Segment by End User to Account the Largest Share in Acute Pancreatitis Market during 2022–2030

According to our latest study on “Acute Pancreatitis Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis" the market is expected to grow from US$ 5,649.77 million in 2022 and is expected to reach US$ 8,827.37 million by 2030; it is anticipated to record a CAGR of 5.7% from 2022 to 2030. The report highlights the acute pancreatitis market insights and key factors driving the acute pancreatitis market growth. The acute pancreatitis market also focus on prominent players with their developments in the market.

Acute pancreatitis is a condition in which the pancreas becomes inflamed over a short period of time. Pancreatitis is of two types — acute pancreatitis meaning it appears suddenly and lasts for days. Some people develop chronic pancreatitis, which is pancreatitis that occurs over many years. Acute pancreatitis is a common disease and a leading cause of hospitalization among gastrointestinal disorders in the global population.

The acute pancreatitis market, by offerings, is segmented into medication, diagnosis, and others. In 2022, the diagnosis segment held the largest share of the market. Moreover, others segment is expected to grow at the fastest rate in the coming years. The acute pancreatitis market for the medications segment is further bifurcated into drug-based therapy and device-based therapy. Similarly, the diagnosis segment is further segmented into blood tests, CT scans, stool tests, ultrasound, MRI, and urine tests.

The acute pancreatitis market, by causes, is segmented into gallstones, alcoholism, genetic disorders, infection, and others. In 2022, the gallstones segment held the largest share of the market. Moreover, the same segment is expected to grow at the fastest rate in the coming years. The acute pancreatitis market, by end user, is segmented into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. In 2022, the hospitals segment held the largest share of the market. However, the diagnostic laboratories segment is estimated to grow at the highest CAGR.

Abbott Laboratories, GE HealthCare Technologies Inc, Samsung Healthcare, Koninklijke Philips NV, Baxter International Inc, Dynavax Technologies Corp, Actim Oy, Medtronic Plc, Boston Scientific Corp, and Fresenius Kabi AG are among the leading companies operating in the global Acute Pancreatitis market.    

Companies operating in the acute pancreatitis market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the acute pancreatitis market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall acute pancreatitis market size growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In May 2023, GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratio, contrast recovery, and quantitative accuracy.
• In May 2023, Royal Philips announced the launch of the Philips CT 3500, a new high-throughput CT system targeting the needs of routine radiology and high-volume screening programs. Powered by AI, the Philips CT 3500 includes a range of image-reconstruction and workflow-enhancing features that help to deliver the consistency, speed, and first-time-right image quality needed for confident diagnoses by clinicians and increased return on investment – even in the most demanding, high-volume care settings.
• In September 2022, GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences. The benefits of AIR Recon DL are extended by these new features to nearly all Magnetic Resonance Imaging (MRI) clinical procedures, covering all anatomies and enabling better image quality, shorter scan times, and enhanced patient experience.
• In December 2021, GE announced that it has completed its previously announced acquisition of BK Medical, a leader in advanced surgical visualization, from Altaris Capital Partners, LLC. With this acquisition, GE Healthcare adds the fast-growing and relatively new field of real-time surgical visualization to GE’s pre- and post-operative Ultrasound capabilities, creating an end-to-end offering through the full continuum of care— from diagnosis through therapy and beyond.
• In October 2020, Royal Philips announced that SimonMed Imaging, one of the largest outpatient imaging providers in the U.S., will bring the most advanced 3T MRI Philips technology to its centers of excellence across the U.S. The first MR systems, placed in California, Arizona, Illinois and Colorado, will feature software and services to enhance diagnoses ranging from brain injuries, liver and cardiac disease, to orthopedic injuries. Philips and SimonMed are also collaborating to further enhance the patient experience and speed in diagnostic imaging.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com